Anti-infective Drug Discovery
Charles River has a strong drug discovery background in infectious disease and the assessment of novel antimicrobials, antivirals, and vaccines. We use a suite of methods to improve your understanding of disease, host interactions, and treatment effects. Disease can be measured using in vitro infectious disease assays, conventional colony-forming units (CFU), or viral titre assessments, combined with clinical disease parameters and pharmacodynamic (PD) analysis. In addition, using protocols pioneered at Charles River, we have the ability to provide data from real-time in vivo bioluminescent imaging (IVIS), allowing you to follow the course of the disease and its treatment.
A broad range of clinically relevant Gram-positive and Gram-negative species can be used in both proof-of-concept PD models and in specialized translational human disease models, all of which can be adapted to run with strains of your choice.
We also offer early screening via our Galleria mellonella model to provide information on compound toxicity and efficacy and help design optimal dosing regimens, including the assessment of combination therapies, prior to use in murine models of infectious disease.
Our bacterial models include:
- Bacterial thigh infection
- Bacterial sepsis
- Bacterial peritonitis
- Bacterial lung infection (acute/chronic)
- Bacterial skin/wound infection
- Urinary tract infection
- Clostridium difficile infection
- Group B streptococcus
Available bacterial strains include multidrug-resistant (MDR) pathogens:
- A. baumannii
- E. coli
- K. pneumoniae
- P. aeruginosa
- Staph. aureus (MSSA and MRSA)
- S. pneumoniae
Specialist viral infection models can be used to test your antivirals and vaccines. These include:
- Herpes simplex virus
- Respiratory syncytial virus
- Encephalomyocarditis virus